Format

Send to

Choose Destination
Clin Pharmacol Ther. 2017 Feb;101(2):220-229. doi: 10.1002/cpt.563. Epub 2016 Dec 20.

Focus on cannabinoids and synthetic cannabinoids.

Author information

1
University Hospital Centre Côte de Nacre, Centre for Evaluation and Information on Pharmacodependance - Addictovigilance (CEIP-A), F-14033, Caen, France.
2
University Hospital Centre Côte de Nacre, Department of Pharmacology, Caen, France.
3
Normandy University, UNICAEN, University Hospital Centre Côte de Nacre, Caen, France.
4
Normandy University, UNICAEN, University Hospital Centre Côte de Nacre, Inserm U 1075 COMETE Caen, France.
5
Medical School, Normandy University, Caen, France.

Abstract

The recent emergence of a multitude of synthetic cannabinoids (SCs) has generated a wealth of new information, suggesting the usefulness of state-of-the-art on lato sensu cannabinoids. By modulating a plurality of neurotransmission pathways, the endocannabinoid system is involved in many physiological processes that are increasingly explored. SCs desired and adverse effects are considered to be more intense than those observed with cannabis smoking, which is partly explained by the full agonist activity and higher affinity for cannabinoid receptors. Neurological and cardiovascular side effects observed after cannabinoid poisoning generally respond to conventional supportive care, but severe outcomes may occur in a minority of cases, mainly observed with SCs. The likelihood of severe abuse and addiction produced by SCs are of concern for the scientific community also interested in the potential therapeutic value of cannabinoids.

PMID:
27861784
DOI:
10.1002/cpt.563
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center